O. M. Parulya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
O. M. Parulya has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Sergey M. Noskov
Yaroslavl State Medical University
3 shared publications - L. S. Shepelyaeva
Yaroslavl State Medical University
2 shared publications - A. V. Kapashin
Valenta Pharm JSC
1 shared publication - A. V. Snigireva
Yaroslavl State Medical University, Ministry of Health of the Russian Federation
1 shared publication - Aleksander A. Globenko
Valenta Pharm JSC
1 shared publication - Alexandra S. Bashkina
Yaroslavl State Pedagogical University named after K. D. Ushinsky
1 shared publication
Latest Publications
- Open Access
- 31 October 2024
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 2 (3) , 21-28
Why is therapeutic exercise the best treatment for knee osteoarthritis?
Osteoarthritis (OA) of the knee joints (KJ) has a high social significance and is therefore a relevant pathology for scientific research. The authors have proposed an original hydraulic theory for the pathogenesis of OA in KJ. This approach is based on the notion of primary mechanical damage to the internal ligamentous structures and synovial membrane accompanied by posttraumatic edema, synovial hypervolemia, and hypertension. The authors demonstrated that regular physical activity at all stages of the disease is pathogenetically justified and allows the patient to improve lymphatic and venous outflow and thus resist increasing fibrosis. Improved arterial blood flow will reduce tissue hypoxia. Any type of symptom-modifying therapy can be harmful because it reduces the protective role of pain reflexes in protecting the KJ from excessive loads, leading to injury. The necessity of maintaining a walking speed of more than 4.3 km/h with an increase in cadence is emphasized from the perspective of reducing static stress during walking and extending life expectancy.
- 31 October 2024
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 2 (3) , 21-28
Open AccessWhy is therapeutic exercise the best treatment for knee osteoarthritis?
Osteoarthritis (OA) of the knee joints (KJ) has a high social significance and is therefore a relevant pathology for scientific research. The authors have proposed an original hydraulic theory for the pathogenesis of OA in KJ. This approach is based on the notion of primary mechanical damage to the internal ligamentous structures and synovial membrane accompanied by posttraumatic edema, synovial hypervolemia, and hypertension. The authors demonstrated that regular physical activity at all stages of the disease is pathogenetically justified and allows the patient to improve lymphatic and venous outflow and thus resist increasing fibrosis. Improved arterial blood flow will reduce tissue hypoxia. Any type of symptom-modifying therapy can be harmful because it reduces the protective role of pain reflexes in protecting the KJ from excessive loads, leading to injury. The necessity of maintaining a walking speed of more than 4.3 km/h with an increase in cadence is emphasized from the perspective of reducing static stress during walking and extending life expectancy.
- Open Access
- 8 August 2024
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 3-11
Study of pharmacokinetic parameters and safety of the drug Duonica® in comparison with the original combination of doxylamine and pyridoxine under fed conditions
Aim. A comparative study of the pharmacokinetics and safety of the investigational drug Duonica®, enteric-soluble, film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia) and the reference drug Diclectin®, delayed-release tablets, 10 mg + 10 mg (Duchesnay Inc, Canada) was conducted as part of the bioequivalence study in healthy volunteers under fed conditions.Material and methods. An open-label randomized crossover two-period bioequivalence study was conducted with 28 Caucasian female volunteers. The study participants were randomly divided into two groups of 14 people depending on the order of drug administration during Periods 1 and 2. Participants randomized to the first group received 2 tablets of Diclectin® during Period 1 and 2 tablets of Duonica® during Period 2. Volunteers from the second group took the study drugs in the reverse order. During each study Period, the drugs were administered after a high-calorie breakfast. The analytes studied were doxylamine and pyridoxal-5-phosphate (an active metabolite of pyridoxine). Methods were developed and validated using high-performance liquid chromatography with a triple quadrupole tandem mass spectrometric detector (HPLC-MS/MS) to quantify the analytes. Pharmacokinetic parameters were calculated from the obtained concentration values and statistical analysis was performed. To confirm bioequivalence, 90 % confidence intervals (CI) for the pharmacokinetic parameters AUC and Cmax of the studied analytes were calculated. The safety of the investigational drugs was assessed based on the frequency, severity and type of adverse events.Results. The 90 % CI values for the ratio of Cmax and AUC(0-t) values for doxylamine were 94.08–113.71 % and 90.63–102.50 %, and for pyridoxal-5-phosphate were 97.34–123.47 % and 90.30–111.03 %, respectively. The obtained CI values were within the limits set by the regulatory requirements and the study protocol (80.00–125.00 %), which allowed us to confirm the bioequivalence of the studied drugs for both components. No adverse events were reported during the study.Conclusion. The study investigated the pharmacokinetics of drugs containing a fixed combination of doxylamine and pyridoxine under fed conditions. The results obtained confirmed the bioequivalence of the drug Duonica® to the reference drug Diclectin®. Both drugs were well tolerated and no differences in the safety profile of the investigational drugs were observed.
- 8 August 2024
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 2,p. 3-11
Open AccessStudy of pharmacokinetic parameters and safety of the drug Duonica® in comparison with the original combination of doxylamine and pyridoxine under fed conditions
Aim. A comparative study of the pharmacokinetics and safety of the investigational drug Duonica®, enteric-soluble, film-coated tablets, 10 mg + 10 mg (Valenta Pharm JSC, Russia) and the reference drug Diclectin®, delayed-release tablets, 10 mg + 10 mg (Duchesnay Inc, Canada) was conducted as part of the bioequivalence study in healthy volunteers under fed conditions.Material and methods. An open-label randomized crossover two-period bioequivalence study was conducted with 28 Caucasian female volunteers. The study participants were randomly divided into two groups of 14 people depending on the order of drug administration during Periods 1 and 2. Participants randomized to the first group received 2 tablets of Diclectin® during Period 1 and 2 tablets of Duonica® during Period 2. Volunteers from the second group took the study drugs in the reverse order. During each study Period, the drugs were administered after a high-calorie breakfast. The analytes studied were doxylamine and pyridoxal-5-phosphate (an active metabolite of pyridoxine). Methods were developed and validated using high-performance liquid chromatography with a triple quadrupole tandem mass spectrometric detector (HPLC-MS/MS) to quantify the analytes. Pharmacokinetic parameters were calculated from the obtained concentration values and statistical analysis was performed. To confirm bioequivalence, 90 % confidence intervals (CI) for the pharmacokinetic parameters AUC and Cmax of the studied analytes were calculated. The safety of the investigational drugs was assessed based on the frequency, severity and type of adverse events.Results. The 90 % CI values for the ratio of Cmax and AUC(0-t) values for doxylamine were 94.08–113.71 % and 90.63–102.50 %, and for pyridoxal-5-phosphate were 97.34–123.47 % and 90.30–111.03 %, respectively. The obtained CI values were within the limits set by the regulatory requirements and the study protocol (80.00–125.00 %), which allowed us to confirm the bioequivalence of the studied drugs for both components. No adverse events were reported during the study.Conclusion. The study investigated the pharmacokinetics of drugs containing a fixed combination of doxylamine and pyridoxine under fed conditions. The results obtained confirmed the bioequivalence of the drug Duonica® to the reference drug Diclectin®. Both drugs were well tolerated and no differences in the safety profile of the investigational drugs were observed.
- Open Access
- 24 January 2024
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 1 (4) , 29-42
Bone marrow edema in osteoarthritis of the knee joint
The term "bone marrow edema" (BME) in MRI examination of the knee joint is used to describe areas of decreased signal intensity on T1-weighted images or increased signal intensity on T2-weighted images in the subchondral bone. BME is classified into ischemic (osteonecrosis), mechanical (trauma), and reactive (arthritis) types. In this review, the causes and differences in BME with spontaneous and secondary osteonecrosis and other characteristics of BME transitioning to a syndrome are considered. BME with injuries and bruises is usually reversible and passes after approximately 2–4 months, if accompanied by a cortical fracture, after 6–12 months. A fatigue fracture develops as a result of repeated overloading of normal bone structures, whereas fractures in zones of subchondral bone insufficiency spontaneously occur in pathologically changed bone tissues (for example, osteoporotic bones) without any trauma or overloading. Histological examination of the damaged subchondral bone in ischemic and mechanical BME revealed hemorrhages, microdestruction of bone trabeculae and vascular anomalies, and almost complete absence of direct edema in MRI-positive zones due to increased extracellular fluid content, which can be partially explained by methodological difficulties in detecting increased extracellular fluid by histopathological methods. Prostacyclin and bisphosphonate have been proposed as conservative therapies for ischemic and mechanical BME.In osteoarthritis (OA) of the knee joints, BME is considered a marker of rapid progression. Data on the influence of obesity, therapeutic exercise and diet, and the use of a cane on BME are presented. Analysis of the effectiveness of conservative therapy revealed a weakly positive response to bisphosphonates. Inhibitors of nerve growth factor (NGF) — monoclonal antibodies to nerve growth factor (like tanezumab and fulranumab) — reduced the severity of pain but led to an increase in the frequency of osteonecrosis and endoprosthesis. Two studies have shown a decrease in the intensity of BME with oral chondroitin sulfate. The attention of orthopedists is focused on subchondroplasty using calcium phosphates. Subchondral filling, which strengthens the bone and replaces the lost barrier function of cartilage, has a symptomatic effect and effectively counteracts the development of BME, although the long-term results need to be studied.
- 24 January 2024
- Published by Publishing House OKI in Patient-Oriented Medicine and Pharmacy
- Vol. 1 (4) , 29-42
Open AccessBone marrow edema in osteoarthritis of the knee joint
The term "bone marrow edema" (BME) in MRI examination of the knee joint is used to describe areas of decreased signal intensity on T1-weighted images or increased signal intensity on T2-weighted images in the subchondral bone. BME is classified into ischemic (osteonecrosis), mechanical (trauma), and reactive (arthritis) types. In this review, the causes and differences in BME with spontaneous and secondary osteonecrosis and other characteristics of BME transitioning to a syndrome are considered. BME with injuries and bruises is usually reversible and passes after approximately 2–4 months, if accompanied by a cortical fracture, after 6–12 months. A fatigue fracture develops as a result of repeated overloading of normal bone structures, whereas fractures in zones of subchondral bone insufficiency spontaneously occur in pathologically changed bone tissues (for example, osteoporotic bones) without any trauma or overloading. Histological examination of the damaged subchondral bone in ischemic and mechanical BME revealed hemorrhages, microdestruction of bone trabeculae and vascular anomalies, and almost complete absence of direct edema in MRI-positive zones due to increased extracellular fluid content, which can be partially explained by methodological difficulties in detecting increased extracellular fluid by histopathological methods. Prostacyclin and bisphosphonate have been proposed as conservative therapies for ischemic and mechanical BME.In osteoarthritis (OA) of the knee joints, BME is considered a marker of rapid progression. Data on the influence of obesity, therapeutic exercise and diet, and the use of a cane on BME are presented. Analysis of the effectiveness of conservative therapy revealed a weakly positive response to bisphosphonates. Inhibitors of nerve growth factor (NGF) — monoclonal antibodies to nerve growth factor (like tanezumab and fulranumab) — reduced the severity of pain but led to an increase in the frequency of osteonecrosis and endoprosthesis. Two studies have shown a decrease in the intensity of BME with oral chondroitin sulfate. The attention of orthopedists is focused on subchondroplasty using calcium phosphates. Subchondral filling, which strengthens the bone and replaces the lost barrier function of cartilage, has a symptomatic effect and effectively counteracts the development of BME, although the long-term results need to be studied.